Mind Medicine (MindMed) Inc.

NasdaqGS MNMD

Mind Medicine (MindMed) Inc. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD 0.00

Mind Medicine (MindMed) Inc. Net Cash Used For Investing Activities is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Mind Medicine (MindMed) Inc. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD 0.00, a 100.00% change year over year.
Mind Medicine (MindMed) Inc. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -297.00 K, a 0.00% change year over year.
Mind Medicine (MindMed) Inc. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD 0.00, a 100.00% change year over year.
Mind Medicine (MindMed) Inc. Net Cash Used For Investing Activities for the year ending August 31, 2019 was USD -213.15 K, a -139.38% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: MNMD

Mind Medicine (MindMed) Inc.

CEO	Mr. Robert Barrow
IPO Date	Nov. 15, 2016
Location	Canada
Headquarters	1055 West Hastings Street
Employees	57
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Mental Health

Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Key trends

Past 5 years